EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?

Nadia Papini iD, Paola Giussani iD, Cristina Tringali iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25168884 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Nadia Papini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, LITA Segrate, 20054 Segrate, MI, Italy. Hauptthemen laut MEDLINE: Metformin, Lysosomes, Neurodegenerative Diseases, Drug Repositioning. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin is a widely employed drug in type 2 diabetes. In addition to warranting good short- and long-term glycemic control, metformin displays many intriguing properties as protection against cardiovascular and neurodegenerative diseases, anti-tumorigenic and longevity promotion. In addition to being a low-cost drug, metformin is generally well tolerated. However, despite the enthusiastic drive to aliment these novel studies, many contradictory results suggest the importance of better elucidating the complexity of metformin action in different tissues/cells to establish its possible employment in neurodegenerative diseases. This review summarises recent data identifying lysosomal-dependent processes and lysosomal targets, such as endosomal Na+/H+ exchangers, presenilin enhancer 2 (PEN2), the lysosomal pathway leading to AMP-activated protein kinase (AMPK) activation, and the transcription factor EB (TFEB), modulated by metformin. Lysosomal dysfunctions resulting in autophagic and lysosomal acidification and biogenesis impairment appear to be hallmarks of many inherited and acquired neurodegenerative diseases. Lysosomes are not yet seen as a sort of cellular dump but are crucial in determining key signalling paths and processes involved in the clearance of aggregated proteins. Thus, the possibility of pharmacologically modulating them deserves great interest. Despite the potentiality of metformin in this context, many additional important issues, such as dosing, should be addressed in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminLysosomesNeurodegenerative DiseasesDrug RepositioningHumansAnimalsHypoglycemic AgentsAutophagy

Stichwörter der Autor:innen

lysosomemetforminneurodegenerative diseases

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, LITA Segrate, 20054 Segrate, MI, Italy.

ORCID-Profile: Nadia Papini, Paola Giussani, Cristina Tringali

Zitieren

APA

Papini, N., Giussani, P., & Tringali, C. (2024). Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168884

Vancouver

Papini N, Giussani P, Tringali C. Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168884

BibTeX
@article{Papini2024,
  author = {Papini, Nadia and Giussani, Paola and Tringali, Cristina},
  title = {Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25168884}
}
Kostenlos starten →